Klose M, Juul A, Poulsgaard L, Kosteljanetz M, Brennum J, Feldt-Rasmussen U
Department of Medical Endocrinology, the University Hospital of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Clin Endocrinol (Oxf). 2007 Aug;67(2):193-201. doi: 10.1111/j.1365-2265.2007.02860.x. Epub 2007 May 24.
To estimate the prevalence and predictive factors of hypopituitarism following traumatic brain injury (TBI).
A cross-sectional cohort study.
One hundred and four hospitalized TBI patients (26F/78M), median age 41 (range 18-64) years, body mass index (BMI) 25 (17-39) kg/m(2); severity: mild [Glasgow Coma Scale (GCS) score 13-15) n = 44, moderate (GCS 9-12) n = 20, severe (GCS < 9) n = 40].
Patients were evaluated 13 (10-27) months post-injury, with measurement of baseline (0800-1000 h) and post-stimulatory hormonal levels during an insulin tolerance test (ITT) (86%) or, if contraindicated, an arginine(arg)-GHRH test + Synacthen test (14%). Insufficiencies were confirmed by retesting.
Hypopituitarism was found in 16 (15%) patients, affecting one axis in 10, two axes in four and more than two axes in two patients. The GH axis was most frequently affected (15%), followed by secondary hypoadrenalism (5%), hypogonadism (2%), hypothyroidism (2%) and diabetes insipidus (2%). The risk of pituitary insufficiency was increased in patients with severe TBI as opposed to mild TBI [odds ratio (OR) 10.1, 95% confidence interval (CI) 2.1-48.4, P = 0.004], and in those patients with increased intracerebral pressure [OR 6.5, 95% CI 1.0-42.2, P = 0.03]. Patients with only one affected axis were all GH deficient; 60% (n = 6) of these were overweight or obese.
The prevalence of hypopituitarism was estimated at 16%. Although high, this value was lower than previously reported, and may still be overestimated because of well-known confounding factors, such as obesity. Indicators of increased TBI severity were predictive of hypopituitarism, with a high negative predictive value. Neuroendocrine evaluation should therefore be considered in patients with severe TBI, and in particular in those with increased intracerebral pressure (ICP).
评估创伤性脑损伤(TBI)后垂体功能减退的患病率及预测因素。
一项横断面队列研究。
104例住院的TBI患者(26例女性/78例男性),中位年龄41岁(范围18 - 64岁),体重指数(BMI)为25(17 - 39)kg/m²;严重程度:轻度[格拉斯哥昏迷量表(GCS)评分13 - 15] n = 44例,中度(GCS 9 - 12)n = 20例,重度(GCS < 9)n = 40例。
患者在受伤后13(10 - 27)个月接受评估,在胰岛素耐量试验(ITT)(86%)期间测量基线(0800 - 1000 h)和刺激后激素水平,或在禁忌时进行精氨酸(arg)-生长激素释放激素(GHRH)试验 + 促肾上腺皮质激素(Synacthen)试验(14%)。通过重新检测确认功能不全。
16例(15%)患者发现垂体功能减退,其中10例影响一个轴,4例影响两个轴,2例影响两个以上轴。生长激素(GH)轴最常受影响(15%),其次是继发性肾上腺皮质功能减退(5%)、性腺功能减退(2%)、甲状腺功能减退(2%)和尿崩症(2%)。与轻度TBI患者相比,重度TBI患者垂体功能不全的风险增加[比值比(OR)10.1,95%置信区间(CI)2.1 - 48.4,P = 0.004],颅内压升高的患者也是如此[OR 6.5,95% CI 1.0 - 42.2,P = 0.03]。仅一个轴受影响的患者均为生长激素缺乏;其中60%(n = 6)超重或肥胖。
垂体功能减退的患病率估计为16%。尽管该值较高,但低于先前报道的值,并且由于肥胖等众所周知的混杂因素,可能仍被高估。TBI严重程度增加的指标可预测垂体功能减退,具有较高的阴性预测价值。因此,对于重度TBI患者,尤其是颅内压(ICP)升高的患者,应考虑进行神经内分泌评估。